Opportunity ID: 338708

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DA-23-004
Funding Opportunity Title: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 16, 2022
Last Updated Date: Mar 16, 2022
Original Closing Date for Applications: Aug 11, 2022
Current Closing Date for Applications: Aug 11, 2022
Archive Date: Sep 16, 2022
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: State governments
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
For profit organizations other than small businesses
City or township governments
Independent school districts
Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This initiative will support exploitation of single cell technologies (transcriptome, epigenome, nucleome, and other emerging single cell assays) to identify the unique molecular features of cells involved in SUDs and/or HIV replication, latency, or reservoirs.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-004.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date

Folder 338708 Full Announcement-RFA-DA-23-004 -> RFA-DA-23-004-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or after January 25, 2022 PKG00272606 Jul 11, 2022 Aug 11, 2022 View

Package 1

Mandatory forms

338708 RR_SF424_5_0-5.0.pdf

338708 PHS398_CoverPageSupplement_5_0-5.0.pdf

338708 RR_OtherProjectInfo_1_4-1.4.pdf

338708 PerformanceSite_4_0-4.0.pdf

338708 RR_KeyPersonExpanded_4_0-4.0.pdf

338708 PHS398_ResearchPlan_4_0-4.0.pdf

338708 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

338708 RR_Budget_3_0-3.0.pdf

338708 RR_SubawardBudget30_3_0-3.0.pdf

338708 PHS398_ModularBudget_1_2-1.2.pdf

338708 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T16:19:44-05:00

Share This Post, Choose Your Platform!

About the Author: